Hear Jennifer Doudna, PhD, on the Giants of Gene Therapy Podcast
Yuliya Klochan, MSJ - March 21, 2023
Jennifer Doudna, PhD, spoke about her personal journey to co-inventing CRISPR-Cas9 for gene editing and the promise of her discovery. ASGCT President Hans-Peter Kiem, MD, PhD, hosted the one-on-one conversation in the fifth episode of ASGCT’s Giants of Gene Therapy.
Jennifer Doudna, PhD, is a professor in the departments of Molecular and Cell Biology and Chemistry at UC Berkeley, and the Li Ka Shing Chancellor’s Professor of Biomedical Science. She’s also the president and co-founder of the Innovative Genomics Institute.
Dr. Doudna has been at UC Berkeley since 2002. In 2020, she earned the Nobel Prize in Chemistry for co-inventing the CRISPR-Cas9 genome editing technology with Emmanuelle Charpentier, PhD.
Outside of her continued work on CRISPR technologies in the lab, Dr. Doudna is a leader in public discussion of the ethical implications of genome editing for human biology and societies.
Dr. Doudna has spoken at the ASGCT Annual Meeting and will be a keynote speaker at this year's Annual Meeting in May, talking about “CRISPR Chemistry and Applications in the Clinic.”
During her one-on-one conversation with ASGCT President Hans-Peter Kiem, MD, PhD, Dr. Doudna spoke about the enormous potential of gene editing and CRISPR technology for the treatment of diseases, diagnostics, drug discovery, and disease prevention. She also shared the personal and educational paths that led her to the CRISPR discovery in 2012.
You can subscribe to the ASGCT channel wherever you listen to your podcasts (including Apple, Spotify, Overcast, Pocket Casts, and more).
Search “ASGCT” in your podcast app to subscribe to the ASGCT Podcast Network
Music by: Steven O'Brien
https://www.steven-obrien.net/
"Making Progress"
(Used for free under a Creative Commons Attribution 4.0 License: https://creativecommons.org/licenses/by/4.0/)
Yuliya Klochan, MSJ, is ASGCT's senior communications manager
Related Articles